In 2018–19, 1,283 publicly funded alcohol and other drug (AOD) treatment services provided just under 220,000 treatment episodes to an estimated 137,000 clients (AIHW)
Bibliography: Domestic Policy Issues
Medical use of cannabis
This briefing provides an overview on the recent change in the law and debate on medicinal cannabis products (House of Commons Library UK)
Family Drug and Alcohol Courts under Covid-19: A Practice Briefing
This briefing examines how the nine existing FDACs across England are adapting to service delivery during the current crisis. It highlights the practical challenges facing practitioners, judges and families, and shines a light on specific solutions that have been developed in response to the Covid-19 pandemic (Centre for Justice Innovation)
Safety of low dose cannabidiol
The review identified that there were potential conditions for low dose cannabidiol that would not require oversight by a medical practitioner. (Australian Government)
Novel benzodiazepines: prevalence and harms in the UK
This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government (ACMD)
Gender and Irish Drug Policy
Report submitted to the working group as part of the ‘Implementing a gender approach in different drug policy areas: from prevention, care and treatment service to law enforcement’ project (UCD)
Standard Operating Procedure for using evidence in ACMD reports
A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice
Delivering health and care for people who sleep rough (PDF)
This research starts to answer the question of what needs to be in place for the delivery of joined-up services to a population of people sleeping rough – as a system, rather than a discrete collection of services (King’s Fund)
Scottish drug misuse database
Overview of Initial Assessments for Specialist Drug Treatment 2018/19 – A National Statistics publication for Scotland
Review of drugs: phase one report
The first part of Dame Carol Black’s independent review of drugs (Home Office)
Trump Administration Seeks Increased Funding to Continue Curbing Drug Crisis
Trump Administration’s Fiscal Year (FY) 2021 National Drug Control Budget, which requests $35.7 billion for counter-drug efforts, an increase of $94 million from the previous year
National Drug Control Strategy 2020 (PDF)
A Report by the Office of National Drug Control Policy
National intelligence network on drug health harms briefing
January 2020 (Public Health England)
Substance misuse treatment in secure settings: 2018 to 2019
Statistics for alcohol and drug misuse treatment in prisons and other secure settings from PHE’s national drug treatment monitoring system (NDTMS)
Release of First-Ever National Clinical Guidelines on Substance Use Disorders among Older Canadians
Canadian healthcare providers now have the tools they need to better support the prevention, assessment and treatment of older adults at risk of, or living with, substance use disorders Canadian Coalition for Seniors’ Mental Health (CCSMH)
Left Behind: The Scale of Illegal Cannabis Use for Medicinal Intent in the UK
In this study, we used a cross-sectional national survey weighted to all adult groups in England, Wales and Scotland to identify this prevalence, and also to scale the monetary and personal costs of use (Centre for Medicinal Cannabis)
Opioids in the United States
The objective of this report is to provide timely information regarding the status of opioids including novel opioids and fentanyl analog prevalence, positivity, and discovery within the United States (NPS)
ACT Pill Testing Trial 2019 (PDF)
Program evaluation (Australian National University)
Needle Syringe Program National Minimum Data Collection Report 2019
The Needle Syringe Program National Minimum Data Collection (NSP NMDC) supports the National Strategies for blood borne and sexually transmissible infections and complements the annual Australian Needle Syringe Program Survey National Data Report (The Kirby Institute, Australia)
Cannabis-based medicinal products (PDF)
This position statement examines the existing evidence on CBMPs and how they relate to mental health (RC PSYCH, UK)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »
